MAPK Signaling

Products for MAPK Signaling
- ERK(72)
- MEK1/2(57)
- NKCC(5)
- MNK(5)
- PKA(49)
- p38(88)
- Rac(2)
- Raf(64)
- RasGAP (Ras- P21)(1)
- JNK(52)
- cAMP(31)
- Protein Kinase G(2)
- RSK(28)
- Other(4)
- MAPKAPK(1)
- MKK(2)
- KLF(3)
- MAP3K(18)
- MAP4K(15)
- MAPKAPK2 (MK2)(9)
- Mixed Lineage Kinase(7)
- Cat.No. Product Name Information
-
GC68350
Tinlorafenib
-
GC67964
Exarafenib
-
GC67905
ERK1/2 inhibitor 7
-
GC67800
B-Raf IN 11
-
GC65978
B-Raf IN 10
B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activity.
-
GC65949
GNE-9815
GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers.
-
GC65917
Andrograpanin
Andrograpanin, a bioactive compound from Andrographis paniculata, exhibits anti-inflammatory and anti-infectious properties.
-
GC65510
ERK1/2 inhibitor 1
ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively.
-
GC65479
PROTAC B-Raf degrader 1
PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity.
-
GC65329
EW-7195
EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung.
-
GC65303
Jaspamycin
Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei.
-
GC65298
DMX-5804
DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96).
-
GC65297
MW-150
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM.
-
GC64904
MAP855
MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2.
-
GC64828
PLX7922
PLX7922, a RAF inhibitor, can bind with BRAFV600E. PLX7922 inhibits pERK in BRAFV600E cell lines, and activates pERK in mutant NRAS cell lines.
-
GC64634
MLK-IN-1
MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1.
-
GC64580
MMI-0100
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2).
-
GC64550
B-Raf IN 2
B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer.
-
GC64496
EF24
EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.
-
GC64460
8-Chloro-cAMP
8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP has anticancer activity.
-
GC64292
MS432
MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2. MS432 displays good plasma exposure in mice, exhibiting DC50 values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively.
-
GC64287
SR15006
SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells).
-
GC64035
Hirsutenone
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects.
-
GC63903
(E)-Osmundacetone
(E)-Osmundacetone is the isomer of Osmundacetone.
-
GC49700
Takeda-6d
-
GC49686
N-desmethyl Regorafenib N-oxide
An active metabolite of regorafenib
-
GC63700
5,6,7-Trimethoxyflavone
5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect.
-
GC63680
MLKL-IN-2
MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i).
-
GC63569
HPK1-IN-4
HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC50 of 0.061 nM) as preclinical immunotherapy tool compound.
-
GC63554
PD0325901-O-C2-dioxolane
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.
-
GC63459
ERK-IN-3 benzenesulfonate
ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK. ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations.
-
GC63441
CC-99677
CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM).
-
GC63425
Zunsemetinib
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.
-
GC63317
HPK1-IN-8
HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1.
-
GC63264
Zapnometinib
Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM.
-
GC63176
Rp-cAMPS sodium salt
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 ?M and 4.5 ?M, respectively) antagonist.
-
GC63144
PF-05381941
PF-05381941 is a potent dual inhibitor of TAK1/p38α, with IC50s of 156 and186 nM, respectively.
-
GC63059
MAP4K4-IN-3
MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay.
-
GC63006
HPK1-IN-7
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1.
-
GC63000
Gypenoside L
Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum.
-
GC49440
ML-9
A PKB/Akt inhibitor
-
GC49285
Adenosine 5’-methylenediphosphate (hydrate)
An inhibitor of ecto-5’-nucleotidase
-
GC49265
PKI (14-22) amide (myristoylated) (trifluoroacetate salt)
A PKA inhibitor
-
GC49241
Methyl Diethyldithiocarbamate
An active metabolite of disulfiram
-
GC49186
O-Demethyl Apremilast
An active metabolite of apremilast
-
GC49150
Tpl2 Kinase Inhibitor (hydrochloride)
A Tpl2 inhibitor
-
GC62675
SM1-71
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.
-
GC62528
(Rac)-Hesperetin
(Rac)-Hesperetin is the racemate of Hesperetin.
-
GC62514
HPK1-IN-3
HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM.
-
GC62504
RAS/RAS-RAF-IN-1
RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity.
-
GC62497
TAK1-IN-2
TAK1-IN-2 is a potent and selective TAK1 inhibitor, with an IC50> of 2 nM.
-
GC62492
CC-90001
CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK).
-
GC62448
Rineterkib hydrochloride
Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
-
GC62426
ASK1-IN-2
ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM.
-
GC62404
p38α inhibitor 2
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6.
-
GC62315
MKK7-COV-9
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.
-
GC62269
RRD-251
RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities.
-
GC62229
ERK-IN-3
ERK-IN-3 is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations.
-
GC62206
PLX-4720-d7
PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
-
GC62146
XST-14
XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects.
-
GC61941
Eudesmin
Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway.
-
GC61865
Cearoin
Cearoin increases autophagy and apoptosis through the production of ROS and the activation of ERK.
-
GC61849
PKI 14-22 amide,myristoylated TFA
PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion.
-
GC61819
MK2-IN-3
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM.
-
GC61747
Sp-cAMPS
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II.
-
GC61512
PKA Inhibitor Fragment (6-22) amide TFA
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM.
-
GC61485
Raf inhibitor 2
Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research.
-
GC61466
DMU-212
DMU-212 is a methylated derivative of Resveratrol, with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of ERK1/2 protein. DMU-212 has orally active.
-
GC61454
GW806742X hydrochloride
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.
-
GC48920
β-Carboline-1-carboxylic Acid
An alkaloid with diverse biological activities
-
GC48652
Olomoucine II
A CDK inhibitor
-
GC48469
Moexipril-d5
An internal standard for the quantification of moexipril
-
GC48381
5'-pApA (sodium salt)
A linearized form of cyclic di-AMP
-
GC48329
PKA Inhibitor (5-24) (trifluoroacetate salt)
A synthetic peptide inhibitor of PKA
-
GC47931
PDE4B Inhibitor
A PDE4B inhibitor
-
GC47771
NG 25 (hydrochloride hydrate)
An inhibitor of MAP4K2 and TAK1
-
GC47166
Dabrafenib-d9
An internal standard for the quantification of dabrafenib
-
GC47088
Cilostazol-d4
An internal standard for the quantification of cilostazol
-
GC47045
Carvedilol-d5
An internal standard for the quantification of carvedilol
-
GC46808
ADTL-EI1712
A dual ERK1 and ERK5 inhibitor
-
GC46554
2'-O-Monosuccinyladenosine-3',5'-cyclic monophosphate
2'-O-Monosuccinyladenosine-3',5'-cyclic monophosphate is a cAMP analog that can be covalently coupled to acetylcholinesterase.
-
GC60886
GSK356278
A selective PDE4 inhbitor
-
GC60812
ERK1/2 inhibitor 2
ERK1/2 inhibitor 2 (Example 1) is a potent dual ERK1/2 inhibitor. ERK1/2 inhibitor 2 has anti-cancer activity.
-
GC60393
(-)-Zuonin A
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively.
-
GC60262
N-Feruloyloctopamine
N-Feruloyloctopamine is an antioxidant constituent. N-Feruloyloctopamine significantly decreases thephosphorylationlevels of Akt and p38MAPK.
-
GC60037
A-3 hydrochloride
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases.
-
GC39815
Semapimod tetrahydrochloride
Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6.
-
GC39485
CK2/ERK8-IN-1
A dual inhibitor of CK2 and ERK8
-
GC39325
2,5-Dihydroxyacetophenone
2,5-Dihydroxyacetophenone, isolated from Rehmanniae Radix Preparata, inhibits the production of inflammatory mediators in activated macrophages by blocking the ERK1/2 and NF-κB signaling pathways.
-
GC50502
RI-STAD 2
AKAP disruptor; selectively binds PKA-RI with high affinity and blocks its interaction with AKAP; cell permeable
-
GC50501
STAD 2
AKAP disruptor; selectively binds PKA-RII and blocks its interaction with AKAP; cell permeable
-
GC50407
st-Ht31 P
Negative control for st-Ht31
-
GC50406
st-Ht31
Inhibits PKA/AKAP interactions; cell permeable
-
GC50400
CC 401 dihydrochloride
High affinity JNK inhibitor; also inhibits HCMV replication
-
GC50316
Org 48762-0
Selective p38α/β inhibitor; orally bioavailable
-
GC50295
TL4-12
Potent MAP4K2 (GCK) inhibitor
-
GC50294
RMM 46
MSK/RSK family kinase inhibitor
-
GC50252
PF 06260933 dihydrochloride
MAP4K4 (HGK) inhibitor; also inhibits MINK and TNIK
-
GC50181
CW 008
PKA signaling activator; promotes osteogenesis from hMSCs
-
GC46123
Comprehensive Kinase Screening Library
For screening of a variety of kinase inhibitors